Volume 10 - Issue 6 - June 2013
Insights
Commentary
06/04/2013
Transcatheter renal denervation has the potential to treat patients with not only hypertension but also renal insufficiency, congestive heart failure, diabetes mellitus, obesity, sleep apnea, and glucose intolerance.
Transcatheter renal denervation has the potential to treat patients with not only hypertension but also renal insufficiency, congestive heart failure, diabetes mellitus, obesity, sleep apnea, and glucose intolerance.
Transcatheter renal denervation...
06/04/2013
Vascular Disease Management
Interview
06/04/2013
The TruePath CTO Device for chronic total occlusion (Boston Scientific), which has a diamond-coated distal tip that spins at 13,000 revolutions per minute, can help to break through extremely calcified lesions.
The TruePath CTO Device for chronic total occlusion (Boston Scientific), which has a diamond-coated distal tip that spins at 13,000 revolutions per minute, can help to break through extremely calcified lesions.
The TruePath CTO Device for...
06/04/2013
Vascular Disease Management
Feature
Case Report
06/04/2013
The authors describe a case of asymptomatic giant AAA that measured 14 cm in diameter.
The authors describe a case of asymptomatic giant AAA that measured 14 cm in diameter.
The authors describe a case of...
06/04/2013
Vascular Disease Management
Review
06/04/2013
Despite encouraging early observations of renal denervation for treatment-resistant hypertension, recent reports in larger patient cohorts have suggested higher than initially reported nonresponder rates. Industry has responded with rapid...
Despite encouraging early observations of renal denervation for treatment-resistant hypertension, recent reports in larger patient cohorts have suggested higher than initially reported nonresponder rates. Industry has responded with rapid...
Despite encouraging early...
06/04/2013
Vascular Disease Management
Case Report
06/04/2013
The authors present a case of endovascular revascularization of a chronic total occlusion via retrograde use of a re-entry catheter, which allows an alternative strategy for revascularization when antegrade approaches fail.
The authors present a case of endovascular revascularization of a chronic total occlusion via retrograde use of a re-entry catheter, which allows an alternative strategy for revascularization when antegrade approaches fail.
The authors present a case of...
06/04/2013
Vascular Disease Management
Column
Clinical Editor's Corner
06/04/2013
The US Food and Drug Administration has approved 21-French and smaller endovascular aneurysm repair (EVAR) systems to include percutaneous EVAR (PEVAR) based on the outcomes of the first prospective, multicenter, randomized PEVAR trial. The...
The US Food and Drug Administration has approved 21-French and smaller endovascular aneurysm repair (EVAR) systems to include percutaneous EVAR (PEVAR) based on the outcomes of the first prospective, multicenter, randomized PEVAR trial. The...
The US Food and Drug...
06/04/2013
Vascular Disease Management
